Abstract
The signaling pathway for IFN-γ–mediated induction of ICAM-1 expression was further studied in human NCI-H292 epithelial cells. The Tyr701 phosphorylation of signal transducer and activator of transcription 1 (STAT1) induced by interferon-γ (IFN-γ) and 12-O-tetradecanoylphorbol 13-acetate (TPA) was inhibited by the protein kinase C (PKC) inhibitor staurosporine, the tyrosine kinase inhibitor herbimycin, or the Src kinase inhibitor PP2. An association between c-Src and STAT1 was increased by IFN-γ and TPA, indicating the direct phosphorylation of STAT1 by PKC-dependent c-Src activation. Tyrosine phosphorylation of Janus kinases (JAK) 1/2 was induced by IFN-γ but not by TPA. In addition, ICAM-1 promoter activity induced by IFN-γ, but not that induced by TPA, was inhibited by the dominant-negative JAK1 and JAK2 mutants. IFN-γ–induced tyrosine phosphorylation of phospholipase C (PLC)-γ was inhibited by AG 490 (a JAK inhibitor), and the association between JAK1/2 and PLC-γ was increased after IFN-γ treatment, indicating the activation of PLC-γ via JAK1/2 phosphorylation. ICAM-1 promoter activities induced by the overexpression of wild-type JAK1- and PLC-γ2 were blocked by the PLCγ2 mutant or the dominant-negative PKCα (Lys→Arg), c-Src (Lys→Met), or STAT1 (Y701M) mutants, but not by dominant-negative STAT3 (DN) mutants. These results confirmed that IFN-γ activated PLC-γ via JAK1/2 phosphorylation to induce PKC, c-Src, STAT1 activation, and ICAM-1 expression. The association between JAK1/2 and STAT1 was increased by IFN-γ but not by TPA. It was inhibited by AG 490 but not by U73122, indicating the possible involvement of the JAK1/2-STAT1 pathway. All the results show that IFN-γ induces ICAM-1 expression by two different pathways in NCI-H292 epithelial cells. One is the JAK1/2-dependent PLC-γ pathway inducing the activations of PKCα, c-Src, and STAT1, and the other is the direct activation of STAT1 by JAK1/2.
- Received May 30, 2003.
- Accepted November 13, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|